Section - CAP Smart Takes

04. Effectiveness of Amphetamine Suspension in ADHD: Day-Long Efficacy

Published on July 1, 2023 Certification expiration date: July 1, 2026

David R. Rosenberg, M.D.

Chair of the Department of Psychiatry & Behavioral Neuroscience - Wayne State University School of Medicine

Key Points

Understanding medication effects' onset, duration, and timing is crucial when prescribing long-acting stimulants. Clinicians and parents often want to ensure the medication remains effective until the end of the school day and beyond.
A study on amphetamine extended-release oral suspension showed rapid, strong, and sustained effects for up to 13 hours after administration in children and adolescents with ADHD, providing reassurance regarding the effectiveness of long-acting stimulants throughout the day and into the evening.

To unlock this audio you need to become a Silver, Gold, Silver extended or Gold extended Member.

Check Our CME Program

Downloads for Offline Access

Download Audio File (MP3)

Text version

Hi! David Rosenberg here for the Psychopharmacology Institute. In this CAP—or Child and Adolescent Psychiatry—Smart Take, we will closely examine critical problems when treating youth with ADHD with stimulants—namely, how rapidly they become effective and helpful and how long their effect persists. There has been a shift in favor of long-acting, extended-release stimulants—methylphenidate and amphetamine—medications, in general, over immediate-release medicines. This is partly because extended-release stimulants have a lower risk for abuse than immediate-release stimulant medicines. However, there are also significant advantages in youth for once-daily dosing rather than immediate-release preparations—typically dosed 2–3 times per day—including doses often needed during the middle of the day and school. Moreover, we also know that treatment adherence is markedly enhanced with once-daily dosing vs multiple daily doses. So, many compelling reasons exist that long-acting and extended-release stimulants have largely taken over as first-line treatments over immediate-release stimulants.

That being said, long-acting stimulants have

Unlock this CAP Smart Take and earn 0.50 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.

Get Instant Access

Already have an account? Sign in

Next Section

05. Pediatric Pharmacogenomic Profiling in the Emergency Department

Learning Objectives:

Evaluate the evidence supporting the use of NAC in reducing alcohol use in adolescents.
Understand the potential role of metformin in managing weight gain associated with second-generation antipsychotic treatment in youth.
Recognize the challenges and dilemmas clinicians face when treating youth with ADHD and co-occurring cannabis use, considering the risks and benefits of different treatment approaches.
Evaluate the effectiveness and duration of action of amphetamine extended-release oral suspension in providing sustained symptom control throughout the day in youth with ADHD.
Understand the potential of pharmacogenomic profiling in guiding medication choices for pediatric patients with psychiatric disorders.

Original Release Date: July 1, 2023

Review and Re-release Date: March 1, 2024

Expiration Date: July 1, 2026

Expert: David Rosenberg, M.D.

Relevant Financial Disclosures:

None of the faculty, planners, and reviewers for this educational activity have relevant financial relationships to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

View the required educational content provided on this course page.
Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.